the University of Jaén

Propanc Biopharma’s Joint Research Partnership with the Universities of Jaén and Granada Enters 13th Year

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Research, Hospitals, Surgery, Genetics, Science, Clinical Trials, the University of Jaén, the University of Granada, Professor Macarena Perán, Professor Juan Marchal, Propanc Biopharma, Inc., THE UNIVERSITY OF JAéN, THE UNIVERSITY OF GRANADA, PROFESSOR MACARENA PERáN, PROFESSOR JUAN MARCHAL, PROPANC BIOPHARMA, INC.

The joint research partnership with the Universities of Jan and Granada has been critical for the advancement of our drug development program at Propanc Biopharma, said Dr. Julian Kenyon.

Key Points: 
  • The joint research partnership with the Universities of Jan and Granada has been critical for the advancement of our drug development program at Propanc Biopharma, said Dr. Julian Kenyon.
  • Furthermore, since international borders appear to have reopened, Dr Kenyon and I plan to visit the joint research team at Granada, Spain, June, 2022.
  • The POP1 joint research and drug discovery program is designed to produce a backup clinical compound to the Companys lead product candidate, PRP.
  • Propanc is undertaking the challenging research project with the Universities of Jan and Granada.

Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Tumor Potential of Proenzymes

Retrieved on: 
Monday, May 17, 2021
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical trials, Science, Surgery, Biotechnology, FDA, Health, Stem cells, Cancer stem cell, Carcinogenesis, Cancer, Radiation therapy, Physical sciences, Branches of biology, Natural sciences, the University of Jaén, the University of Granada, Propanc Biopharma, Inc., THE UNIVERSITY OF JAéN, THE UNIVERSITY OF GRANADA, PROPANC BIOPHARMA, INC.

Treatment with proenzymes sensitizes cancer stem cells (CSCs) which may allow standard treatment approaches, like chemotherapy and radiotherapy to be more effective.

Key Points: 
  • Treatment with proenzymes sensitizes cancer stem cells (CSCs) which may allow standard treatment approaches, like chemotherapy and radiotherapy to be more effective.
  • Expert Opinion on Biological Therapy is a peer-reviewed medical journal covering research on all aspects of biological therapies.
  • The article is entitled \xe2\x80\x9cTrypinsogen and chymotrypsinogen: potent anti-tumor agents,\xe2\x80\x9d and can be accessed via the link: https://www.tandfonline.com/eprint/MJ7Y7EWCJI9CHESREZUC/full?target=10.1...\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210517005041/en/\nMain anti-tumor effects of Proenzymes (Photo: Business Wire)\nThe article is the fifth scientific publication published on the effects of proenzymes in cancer and fourth published in a peer reviewed journal.

Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes

Retrieved on: 
Tuesday, August 13, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Stem cells, Research, University, Education, Science, Clinical trials, Biotechnology, Health, Pharmaceutical, Oncology, Stem cells, Research, University, Education, Science, Clinical trials, RTT, Cancer, Cancer treatments, the University of Jaén, the University of Granada, Propanc Biopharma, Inc.

From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences.

Key Points: 
  • From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences.
  • This is likely to translate into PRP being effective in many different cancer types and reducing the recurrence rate after standard treatments.
  • The data provides the strongest evidence that proenzymes could be an effective tool in the fight against metastatic cancer, the single biggest cause of patient death for sufferers.
  • The companys lead product candidate, PRP, is a formulation of two proenzymes, designed to act synergistically against solid tumors which are malignant.